The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population

Gene

Volumn 527, Issue 1, 2013, Pages 301-305

  Ayaz, Gulsel ^a   Batar, Bahadir ^a   Kanigur, Gonul ^a   Guven, Mehmet ^a   Onaran, Ilhan ^a   Karadag, Bilgehan ^a   Ilerigelen, Baris ^a   Dirican, Ahmet ^b   Ulutin, Turgut ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; ELISA; MDR1; PCR; Platelet activating factor; Polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

CAD; CORONARY ARTERY DISEASE; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; MDR1; MULTIDRUG-RESISTANCE 1; P-GLYCOPROTEIN; P-GP; PAF; PCR; PLATELET ACTIVATING FACTOR; POLYMERASE CHAIN REACTION; POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RFLP;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-GLYCOPROTEIN; PLATELET ACTIVATING FACTOR; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TURKEY;

EID: 84881239045     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.06.046     Document Type: Article

References (40)

1. Ameway M., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11:217-221.
2. Burger H., et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 2003, 9:827-836.
3. Campa D., et al. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One 2012, 7:1-7.
4. Cascorbi I., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001, 69:169-174.
5. Cascorbi I., Kroemer H.K., Siegmund W. Pharmacogenetics of P-gp mediated drug transport. Nova. Acta Leopoldina 2003, 329:93-100.
6. Chao W., Olson M.S. Platelet-activating factor: receptor and signal transduction. Biochem. J. 1993, 292:617-629.
7. Chen H., et al. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clin. Oral Investig. 2010, 14:629-636.
8. Clark A.G. The role of haplotypes in candidate gene studies. Genet. Epidemiol. 2004, 27:321-333.
9. Demopoulos C.A., Karantonis H.C., Antonopoulou S. Platelet activating factor-A molecular link between atherosclerosis theories. Eur. J. Lipid Sci. Technol. 2003, 105:705-716.
10. Ernest S., Bello-Reuss E. Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J. Am. Soc. Nephrol. 1999, 10(11):2306-2313.
11. Fromm M.F. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002, 181-182:299-303.
12. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug. Discov. 2005, 4:664-672.
13. Hoffmeyer S., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3473-3478.
14. Kang T.Y., et al. Elevated platelet activating factor level in ischemia-related arrhythmia and its electrophysiological effect on myocardium. Biomed. Environ. Sci. 2013, 26:365-370.
15. Kerb R. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001, 1:204-210.
16. Kimchi-Sarfaty C., et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
17. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
18. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
19. Lupia E., et al. Intra-plaque production of platelet-activating factor correlates with neoangiogenesis in human carotid atherosclerotic lesions. Int. J. Mol. Med. 2003, 12:327-334.
20. Miwa A., et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 1988, 82:1983-1991.
21. Montrucchio G., Alloatti G., Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Phys. Rev. 2000, 80(4):1669-1699.
22. Mueller H.W., et al. Measurement of platelet-activating factor in a canine model coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ. Res. 1995, 77(1):54-63.
23. Ninio E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr. Opin. Clin. Nutr. Metab. Care. 2005, 8:123-131.
24. Oh S.O., Ibe B.O., Johnson C., Kurantsin-Mills J., Raj J.U. Platelet-activating factor in plasma of patients with sickle cell disease in steady state. J. Lab. Clin. Med. 1997, 130:191-196.
25. Penna C., Bassino E., Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp. Biol. Med. (Maywood) 2011, 236:390-401.
26. Raggers R.J., Vogels I., Meer G.V. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem. J. 2001, 357:859-865.
27. Ross R. Atherosclerosis an inflammatory disease. N. Engl. Med. 1999, 340:115-126.
28. Sakaeda T. MDR1 genotype-related pharmacogenetics: fact or fiction?. Drug Metab. Pharmacokinet. 2005, 20:391-414.
29. Sapmaz, et al. Effects of polymorphism in G267T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease. Turk. J. Gastroenterol. 2008, 19:168-173.
30. Schwab M., Eichelbaum M., Fromm M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 2003, 43:285-307.
31. Shin C.R., Moores J., Best A.M., Tew J.G., Schenkein H.A., Barbour S.E. Differential platelet-activating factor synthesis by monocytes and polymorphonuclear leukocytes from subjects with localized aggressive periodontitis. J. Periodontol. Res. 2007, 42:202-211.
32. Sills G.J., et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005, 46:643-647.
33. Sipeky, et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug Metab. Pharmacokinet. 2011, 26:206-215.
34. Stram D.O. Tag SNP selection for association studies. Genet. Epidemiol. 2004, 27:365-374.
35. Subbanagounder G., Leitinger N., Shih P.T., Faull K.F., Berliner J.A. Evidence that phospholipids oxidation products and/or platelet activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circ. Res. 1999, 85:311-318.
36. Tanabe M., et al. Expression of P-glycoprotein in Human Placenta: Relation to Genetic Polymorphism of the Multidrug Resistance (MDR)-1 Gene. J. Pharmacol. Exp. Ther. 2001, 297:1137-1143.
37. Vadas P., et al. Platelet activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 2008, 358:28-35.
38. Van Helvoort A., et al. MDR1 P-Glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (Cambridge, Mass.) 1996, 87:507-517.
39. Zhao L., Funk C.D. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 2004, 14:191-195.
40. Zheng G.H., Xiong S.Q., Mei L.J., Chen H.Y., Wang T., Chu J.F. Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case-control study. Inflammation 2012, 35:1419-1428.